|
W3C
Reset Setting Change font size to lower sizeChange font size to original sizeChange font size to large size
    T
    T
    T
    T
    T
    T
Clinical evaluation of Buserelin, a GnRH analogue in the management of moderate to severe pelvic endometriosis


View Attachment
:
 13
 Downloads
Item type Article
Subjects 600 Technology > 610 Medicine & health
Division/Agency LPPKN - National Population and Family Development Board, Malaysia: Human Reproductive Division
Keywords Treatment of endometriosis, Female infertility
Additional Information The hard copy can be refer at Resource Center, NPFDB.
Abstract A local study, a part of a multinasional and multicenter study on the efficacy and safety of Buserelin was carried out for the treatment of pelvic endometriosis using a standard protocol. 20 women diagnosed to have moderate to severe endometriosis by laparoscopy were recruited. The women were given 900 micrograms Buserelin acetate daily by intranasal spray for a fixed period of 6 months. Baseline hormonal and biochemical parameters were taken prior to treatment and the parameters were repeated during each follow-up at weekly and monthly intervals. In addition, changes in symptoms were monitored. A second look laparoscopy was performed at completion of therapy and patients were followed up for a further 6 months. There was 100 percent suppression of oestradiol levels during the 6 months treatment period. An improvement of implants according to AFS classification occured in all patients. One patient discontinued because of side effects. Restoration of cycles after completion of therapy occured within 7 weeks. There were 7 pregnancies (64%) in the first 6 months after treatment for those wanting pregnancies. During therapy, dysmenorrhoea, pelvic pain and dyspareunia improved considerably. Buserelin was proven to be effective in the management of pelvic endometriosis and is well tolerated and safe.
:
 13
 All Downloads